RxDoctor Payments Data

Marc Krock, MD

Interventional Cardiology · McKinney, TXNPI 1265496426

Payments from drug & device makers

$82,676in general payments, 2019–2025

Across 675 payments — averaging $122.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$58K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$10K
  • Novartis$2K
  • Boston Scientific$2K
  • Impulse Dynamics (USA) Inc.$1K
  • Abbott$1K
  • plus $8K from 43 others

What the payments were for

  • Consulting fees$1,1221%
  • Speaking & faculty fees$63,00076%
  • Travel & lodging$2,3763%
  • Food & beverage$16,15720%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,676 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$329,054
Medicare patients
754
Services billed
4,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban75$88,309
EliquisApixaban75$72,639
JardianceEmpagliflozin45$67,278
EntrestoSacubitril/Valsartan11$21,404
MultaqDronedarone Hcl12$19,382
FarxigaDapagliflozin Propanediol16$15,427
Hydralazine Hcl149$2,695
Valsartan83$2,210
Metoprolol Succinate98$1,319
Rosuvastatin Calcium81$1,149
Nebivolol Hcl15$941
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$819
Isosorbide Dinitrate12$789
Carvedilol72$676
Losartan Potassium42$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$454$88,30975 claims
PfizerEliquis$218$72,63975 claims
Boehringer IngelheimJardiance$120$67,27845 claims
NovartisEntresto$2,345$21,40411 claims
Sanofi-aventis U.S. LLCMultaq$630$19,38212 claims
AstraZenecaFarxiga$57,864$15,42716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →